Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06012448 · ClinicalTrials.gov registry record · Phase 4
The Immunologic Effects of Dupilumab in the Treatment of Dermal Hypersensitivity Reaction
A Phase 4 study of Dermal Hypersensitivity Reaction, sponsored by University of Michigan.
- Completed
- Registry status
- Phase 4
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT06012448 is a Phase 4 study of Dermal Hypersensitivity Reaction that has completed, run by University of Michigan. The registered enrollment target is 10 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06012448, a Phase 4 study of Dermal Hypersensitivity Reaction, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This research is studying a drug called dupilumab to learn about its safety and its effect as a treatment for participants with dermal hypersensitivity reaction. This study will help better understand why and how dermal hypersensitivity reaction occurs and how dupilumab might help treat this condition.
Conditions Studied
Interventions
- DRUG Dupilumab
Study Locations (1)
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2023-10-02 |
| Est. Completion | 2025-03-25 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06012448
The ClinicalTrials.gov registry entry for NCT06012448 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dermal Hypersensitivity Reaction appearing as the primary indexed condition, and to 1 intervention - of which Dupilumab is the first listed.
NCT06012448 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT06012448 about?
NCT06012448 is a clinical study titled "The Immunologic Effects of Dupilumab in the Treatment of Dermal Hypersensitivity Reaction". This research is studying a drug called dupilumab to learn about its safety and its effect as a treatment for participants with dermal hypersensitivity reaction. This study will help better understand why and how dermal hypersensitivity reaction occurs and how dupilumab might help treat this conditi...
What is the current status of trial NCT06012448?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2023-10-02. Estimated completion is 2025-03-25.
What conditions does trial NCT06012448 study?
This clinical trial studies the following conditions: Dermal Hypersensitivity Reaction.
What interventions are being tested in trial NCT06012448?
The interventions under investigation include: Dupilumab (DRUG).
Who is sponsoring clinical trial NCT06012448?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06012448 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.